We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MDRNA, Inc. Announces Research Study With Pfizer
News

MDRNA, Inc. Announces Research Study With Pfizer

MDRNA, Inc. Announces Research Study With Pfizer
News

MDRNA, Inc. Announces Research Study With Pfizer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MDRNA, Inc. Announces Research Study With Pfizer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MDRNA, Inc. has announced a study effort with Pfizer. The relationship will focus on the evaluation of MDRNA's proprietary di-alkylated amino acids (DiLA2) platform and UsiRNA constructs for RNA interference (RNAi).

Additional details of the collaboration were not disclosed. This marks MDRNA's fourth early collaborative effort announced with a major pharmaceutical company in the past nine months.

MDRNA will be responsible for formulating Pfizer's oligonucleotides in DiLA2 formulations for in vivo preclinical evaluation to be performed at Pfizer. Additionally, MDRNA's research team will design and synthesize UsiRNAs directed against targets specified by Pfizer.

"We are extremely pleased to be working with Pfizer, a world leader in the pharmaceutical industry," said Michael French, President and CEO of MDRNA. "As Pfizer has made a commitment to the research and development of RNAi therapeutics, this is a significant opportunity for MDRNA to again demonstrate the broad capabilities of its world-class research team and proprietary drug discovery engine for RNAi-based therapeutics."
Advertisement